Aptarion Biotech AG
π©πͺGermany
- Country
- π©πͺGermany
- Ownership
- Private
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.aptarion.com
Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Aptarion Biotech AG
- Target Recruit Count
- 150
- Registration Number
- NCT05962606
- Locations
- π©πͺ
University Hospital Cologne, Cologne, Germany
π§πͺCliniques Universitaires Saint-Luc, Brussels, Belgium
π§πͺClinique Saint Pierre, Ottignies, Belgium
Ascending Multiple Intravenous Doses of AON-D21 in Healthy Male Subjects.
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- Aptarion Biotech AG
- Target Recruit Count
- 16
- Registration Number
- NCT05343819
- Locations
- π©πͺ
Nuvisan GmbH, Neu-Ulm, Germany
First-in-human Trial With Single-dose C5a-neutralizing AON-D21 in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Intravenous AON-D21Drug: Intravenous placebo
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- Aptarion Biotech AG
- Target Recruit Count
- 40
- Registration Number
- NCT05018403
- Locations
- π©πͺ
Nuvisan GmbH, Neu-Ulm, Germany
Β© Copyright 2025. All Rights Reserved by MedPath